Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress wnt/β-catenin signaling

Molecular Cancer Therapeutics

Volumn 12, Issue 9, 2013, Pages 1848-1858

  Li, Nan ^a   Xi, Yaguang ^c   Tinsley, Heather N ^d   Gurpinar, Evrim ^a   Gary, Bernard D ^c   Zhu, Bing ^c   Li, Yonghe ^b   Chen, Xi ^c   Keeton, Adam B ^c   Abadi, Ashraf H ^e   Moyer, Mary P ^f   Grizzle, William E ^a   Chang, Wen Chi ^g   Clapper, Margie L ^g   Piazza, Gary A ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d UNIVERSITY OF MONTEVALLO   (United States)

^e German University in Cairo   (Egypt)

^f Departments of INCELL ^*  (United States)

^g FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIC GMP; SULINDAC; WNT PROTEIN;

ARTICLE; CANCER GROWTH; COLON CANCER; DOWN REGULATION; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CACO-2 CELLS; CARBOLINES; CELL LINE; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYCLIN D1; HCT116 CELLS; HT29 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SULFONES; SULINDAC; WNT SIGNALING PATHWAY;

EID: 84883614821     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0048     Document Type: Article

References (46)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Wingo PA, Ries LA, Parker SL, HeathCWJr. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998;7:271-82.
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
4. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and coloncancer chemoprevention. Lancet Oncol 2002;3:166-74.
5. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
6. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
7. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
8. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
9. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-52.
10. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997;40: 344-9.
11. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996;17:1757-60.
12. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998;19:87-91.
13. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57:2909-15.
14. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994;107:854-7.
15. Alberts DS, Hixson L, Ahnen D, Bogert C, Einspahr J, Paranka N, et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 1995;22:18-23.
16. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase- 2. J Pharmacol Exp Ther 2005;314:1-8.
17. Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 1999;470:45-53.
18. Arber N, Kuwada S, Leshno M, Sjodahl R, Hultcrantz R, Rex D, et al. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut 2006;55:367-73.
19. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, WhiteheadCM, Liu L, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001;61:3961-8.
20. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, et al. Exisulind induction of apoptosis involves guanosine 30,50-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-42.
21. Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, et al.Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res 2010;3:1303-13.
22. Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB. Celecoxibinduced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 2008;47: 519-25.
23. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011;91:651-90.
24. Pastan IH, Johnson GS, Anderson WB. Role of cyclic nucleotides in growth control. Annu Rev Biochem 1975;44:491-522.
25. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res 2011;4:1275-84.
26. Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009;8:3331-40.
27. Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, et al.Anovel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and beta-catenin transcriptional activity. Cancer Prev Res 2012;5:822-33.
28. Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim 1996;32:315-7.
29. Li Q, Dashwood WM, Zhong X, Al-Fageeh M, Dashwood RH. Cloning of the rat beta-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters. Genomics 2004;83:231-42.
30. Deguchi A, Soh JW, Li H, Pamukcu R, Thompson WJ, Weinstein IB. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther 2002;1:803-9.
31. Han A, Song Z, Tong C, Hu D, Bi X, Augenlicht LH, et al. Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol 2008;583:26-31.
32. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, et al. Sulindac metabolites induce caspase- and proteasome-dependentdegradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2003;2:885-92.
33. Chang WC, Everley LC, Pfeiffer GR 2nd, Cooper HS, Barusevicius A, Clapper ML. Sulindac sulfone is most effective in modulating betacatenin- mediated transcription in cells with mutant APC. AnnNY Acad Sci 2005;1059:41-55.
34. Li H, Liu L, David ML, Whitehead CM, Chen M, Fetter JR, et al. Proapoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 2002;64:1325-36.
35. Kwon IK, Wang R, Thangaraju M, Shuang H, Liu K, Dashwood R, et al. PKG inhibits TCF signaling in colon cancer cells by blocking betacatenin expression and activating FOXO4. Oncogene 2010;29: 3423-34.
36. Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, et al. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther 2001; 299:583-92.
37. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21: 3454-61.
38. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479-88.
39. Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, et al. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res 2009;2: 572-80.
40. Davies NM, Watson MS. Clinical pharmacokinetics of sulindac: a dynamic old drug. Clin Pharmacokinet 1997;32:437-59.
41. Anderson CB, Neufeld KL, White RL. Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon. Proc Natl Acad Sci U S A 2002;99:8683-8.
42. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90.
43. Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000;60:1671-6.
44. Lu W, TinsleyHN, Keeton A,QuZ, Piazza GA, Li Y. Suppression of Wnt/ beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 2009;602:8-14.
45. Clapper ML, Coudry J, Chang WC. beta-catenin-mediated signaling: a molecular target for early chemopreventive intervention. Mutat Res 2004;555:97-105.
46. Sang J, Chen Y, Jiang L, Tao Y, Wu Y, Wang Y, et al. Type II cGMPdependent protein kinase inhibits ERK/JNK-mediated activation of transcription factors in gastric cancer cells. Mol Med Rep 2012;6: 1190-4.